Cancer Immunotherapy: New Pathways and Innovating Therapeutics (R3)
January 1-5, 2028
| Location to be Determined
Niroshana Anandasabapathy
| 4:00–8:00 PM |
Registration |
|
| 6:00–8:00 PM |
Welcome Mixer |
|
Tuesday, January 18, 2028
| 8:00–8:10 AM |
Welcome Remarks |
|
| 8:10–9:00 AM |
Keynote Address |
|
| |
Fred J. Ramsdell †, Sonoma Biotherapeutics
Why I Won the Nobel Prize, and the Relevance to Cancer Immunotherapy |
|
| 9:00–11:15 AM |
Frankensteining the Future: Transformative Technologies, Next Generation Screens, and AI-based Responses |
|
| |
Benjamin Izar †, Columbia Universtiy Medical Center
Base Editing Screens Advancing IO |
|
| |
Aviv Regev †, Genentech
The future of IO |
|
| |
Ashley Lakner †, Roche
Directing Early-Stage Discovery Pipelines Focused on Novel Cancer Immunotherapies |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:30–9:50 AM |
Coffee Break |
|
| 11:25–12:25 PM |
Panel Discussion and Debate 1: Spectacular Failures and what we Learned: Why have Checkpoints Failed Beyond PD1; CAR Failures and what was Learned |
|
| 12:25–1:30 PM |
Poster Setup |
|
| 12:25–5:00 PM |
On Own for Lunch |
|
| 1:30–10:00 PM |
Poster Viewing |
|
| 2:30–4:30 PM |
Symposia Spotlight 1: Novel Antigen Targets for ADC and T Cell Engager |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
New Antigen Spaces, Immune Editing, and the Bystander Crowd |
|
| |
Yardena Samuels, Weizmann Institute of Science
Neoantigens in Cancer |
|
| |
Evan W. Newell †, Fred Hutchinson Cancer Research Center
The Bystander Effect, Viral Responses Shaping Tumor Immunity |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| |
Özlem Türeci †, BioNTech
Transformative Vaccine Strategies for Cancer Care |
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
Wednesday, January 19, 2028
| 8:00–11:00 AM |
Spectacular Wins and Failures in IO: Lessons Learned and Alternative Paths |
|
| |
Saar I. Gill †, University of Pennsylvania
Balancing Failures with New Directions: What Works and Why? |
|
| |
Jennifer Ann Wargo †, University of Texas MD Anderson Cancer Center
Microbiome and Cancer: The Bumpy Road to Success |
|
| |
Jedd D. Wolchok †, Weill Cornell Medicine
The Bermuda Triangle of IO: TIGIT, IDO, LAG3 |
|
| |
Yvonne Y. Chen †, University of California, Los Angeles
Biomolecular Engineering and Synthetic Biology Approaches to Enhance CARs |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–1:00 PM |
Poster Setup |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 3:00–4:30 PM |
Career Roundtable |
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
IO DJs: Modulating Innate and Adaptive Immune Circuits |
|
| |
Ana Carrizosa Anderson †, Harvard Medical School
Emerging T Cell Targets from Basic Discovery |
|
| |
Andrea Schietinger †, Memorial Sloan Kettering Cancer Center
Tumor Immune Triads |
|
| |
Paul G. Thomas †, Fred Hutchinson Cancer Center
What Really Dictates Successful Immunity to Flu and Cancer |
|
| |
Thorsten R. Mempel †, Massachusetts General Hospital
Homing, Chemokines, and Trafficking Tumor Immunity |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
Thursday, January 20, 2028
| 8:00–11:00 AM |
Translating Myeloid Biology to New Targets, and Alternatives |
|
| 8:00–11:00 AM |
Panel Discussion and Debate 2: Suboptimal Priming vs. Hostile TME. TAA/Neoantigen/Bystander: What Really Matters and Why? |
|
| |
David Sancho †, Centro Nacional de Investigaciones Cardiovasculares, CNIC
Tumor Immune Escape, Targeting Immunosuppressive Macrophages, and Alternatives |
|
| |
Mikael J Pittet †, University of Geneva
Pivoting from Macrophage Targets to CCR7+ Migratory DC in Cancer |
|
| |
Niroshana Anandasabapathy, Weill Cornell Medicine
Drivers of Immune Related Adverse Events: A Failure in IO or a Spectacular Success? |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 2:30–4:30 PM |
Symposia Spotlight 2: Tumor Immune Resistance |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–6:45 PM |
Immune Set Points in Cancer |
|
| |
Charles G. Drake, Johnson and Johnson
New Pharma Approaches |
|
| |
Kole T. Roybal †, University of California, San Francisco
Cellular Engineering, Translation, and Paving the Way to Industry |
|
| |
Haydn Kissick †, Emory University
Setpoints Driving TCF7, Immune Memory, and Successful IO Responses |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 6:45–7:00 PM |
Meeting Wrap-Up: Outcomes and Future Directions |
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 PM |
Entertainment |
|
